Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature

Immune checkpoint inhibitors are known to cause a variety of immune-related adverse events, including pneumonitis. When symptomatic, treatment typically consists of temporary or permanent cessation of the checkpoint inhibitor and several weeks of corticosteroid therapy. However, a subset of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Petri, Camille R., Patell, Rushad, Batalini, Felipe, Rangachari, Deepa, Hallowell, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456450/
https://www.ncbi.nlm.nih.gov/pubmed/31008047
http://dx.doi.org/10.1016/j.rmcr.2019.100834

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6456450/
https://www.ncbi.nlm.nih.gov/pubmed/31008047
http://dx.doi.org/10.1016/j.rmcr.2019.100834

Ejemplares similares